Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

This makes the new indication for Dupixent very important for Sanofi as it searches for a blockbuster to transform its fortunes. The FDA is set to make a decision on Dupixent’s new indication on ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

The recent approval and launch in chronic obstructive pulmonary disease (COPD) have had a successful start, with coverage secured from the top commercial and Medicare payers. Dupixent is now well ...

Dupixent pen and syringe are two different devices used to inject the drug. They’re prefilled with the same amount of Dupixent and share other features, but certain factors make the pen easier ...

Dupixent remains in the running to become a ... but with biosimilars to Xolair looming it is uncertain about the commercial potential of the drug. It's waiting on the results of trials in addition ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...

Furthermore, the successful launch of Dupixent for chronic obstructive pulmonary disease (COPD) has garnered significant coverage from top commercial and Medicare payers, indicating strong market ...

Dupixent ® is now used to treat over a million ... with the most advanced programs addressing an aggregate commercial market opportunity expected to exceed $220 billion by 2030.